The topics that will be covered in the course include:

- Next generation sequencing
- Novel findings in breast, colorectal, ovarian, endometrial and kidney cancers
- Novel findings in colorectal, ovarian, endometrial and kidney cancers
- Targeted therapy in melanoma
- KIT and novel targets in gastrointestinal stromal tumours
- Genetic testing in colorectal and lung cancers
- Translocations in sarcomas and haematological malignancies
- The role of pathologists in precision medicine
- Molecular tumour boards
- How to deliver molecular tests for clinical decision-making
- Causes of possible pitfalls in molecular analysis.

Course Overview

Genomic analyses of human cancers are leading to the identification of the genetic determinants of cancer development, progression and response to targeted therapies. Treatment decisions selecting therapies for cancer patients can no longer be solely based on histopathological analyses of tumours. In fact, molecular tests are rapidly being incorporated into routine clinical practice. The role of pathologists in the implementation of molecular tests in diagnostic practice and the ability of pathology laboratories to perform these tests in an optimal manner are crucial for the successful translation of scientific advancements into useful biomarkers. In addition, a multidisciplinary approach for the delivery of optimal molecular characterisation of cancers is essential for the realization of the promises of precision medicine.

Scientific Organising Committee

Richard Marais (UK)
Jorge Reis-Filho (USA)
Giorgio Stanta (Italy)
Marc van de Vijver (Netherlands)

Invited Speakers

Judith Bovee (Netherlands)
David Huntsman (Canada)
A. John Iafrate (USA)
Andreas Jung (Germany)
Richard Marais (UK)
Serena Nik-Zainal (UK)
Stefan Pfister (Germany)
Jorge Reis-Filho (USA)
Brian Rubin (USA)
Anne Schultheis (USA)
Tim Somervaille (UK)
Giorgio Stanta (Italy)
Erik Thunissen (Netherlands)
Matt van de Rijn (USA)
Marc van de Vijver (Netherlands)
Pieter Wesseling (Netherlands)
Andrew Wotherspoon (UK)